| Abstract: | An announcement by the Food and Drug Administration approving limited use of Depo Provera (medroxyprogesterone acetate) as an injectable contraceptive agent is reported. The drug is quite effective as a contraceptive agent, but may result in infertility after discontinuation of use, and has adverse effects similar to those associated with oral contraceptives. The accompanying physician labeling advises that the drug be prescribed only to patients who accept the possibility that they may not be able to become pregnant after discontinuing use, and those who cannot accept or tolerate other contraceptive methods. Medroxyprogesterone acetate is already in use in the distribution and monitoring the results of its use have been issued. |
